Regulatory and reimbursement challenges for molecular imaging

Radiology

Volumn 245, Issue 3, 2007, Pages 645-660

  Hoffman, John M ^a   Gambhir, Sanjiv S ^b   Kelloff, Gary J ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GADODIAMIDE; GADOLINIUM PENTETATE; IODIXANOL; IOHEXOL; IOPAMIDOL; IOPROMIDE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOACTIVE MATERIAL; TETROFOSMIN TC 99M;

ALZHEIMER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DEMENTIA; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; ECHOGRAPHY; FOOD AND DRUG ADMINISTRATION; FRONTOTEMPORAL DEMENTIA; HEALTH INSURANCE; HOSPITAL BILLING; HUMAN; IMAGING SYSTEM; MEDICAID; MEDICAL RESEARCH; MEDICARE; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; REIMBURSEMENT; REVIEW; X RAY;

COSTS AND COST ANALYSIS; DIAGNOSTIC IMAGING; MOLECULAR DIAGNOSTIC TECHNIQUES; REIMBURSEMENT MECHANISMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 36349016646     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2453060737     Document Type: Review

References (59)

1. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA 2005;297:855-862.
2. Jager PL, de Korte MA, Lub-de Hooge MN, et al. Molecular imaging: what can he used today. Cancer Imaging 2005;23(5 suppl): S27-S32.
3. Pomper MG. Translational molecular imaging for cancer. Cancer Imaging 2005;23(5 suppl):S16-S26.
4. Landini L, Santarelli MF, Positano V, Leone A. Molecular imaging: its application in cardiovascular diagnosis. Curr Pharm Des 2005;11(17):2225-2234.
5. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003;17(5):545-580.
6. Hillman BJ, Neiman HL. Translating molecular imaging research into radiologic practice: summary of the proceedings of the American College of Radiology Colloquium, April 22-24, 2001. Radiology 2002;222(1):19-24.
7. Hicks RJ. The role of PET in monitoring therapy. Cancer imaging 2005;5(1):51-57.
8. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11(8): 2785-2808.
9. Cyrus T, Winter PM, Caruthers SD, Wickline SA, Lanza GM. Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Export Rev Cardiovasc Ther 2005;3(4): 705-715.
10. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005;11(22):7967-7985.
11. Wang J, Manrer L. Positron emission tomography: applications in drug discovery and drug development. Curr Top Med Chem 2005;5(11):1053-1075.
12. Eckelman WC, Rohatagi S, Krohn KA, Vera DR. Are there lessons to be learned from drug development that will accelerate the use of molecular imaging probes in the clinic? Nucl Med Biol 2005;32(7):657-662.
13. Rudin M. Molecular imaging: basic principles and applications in biomedical research. London, England: Imperial College Press, 2005.
14. Rudin M, Rausch M, Stoeckli M. Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods. Mol Imaging Biol 2005;7(1):5-13.
15. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2003;2(2):123-131.
16. The critical path to new medical products. U.S. Food and Drug Administration Web site. http://www.fda.gov/oc/initiatives /criticalpath/. Published March 16, 2004. Accessed September 3, 2007.
17. Challenge and opportunity on the critical path to new medical products. U.S. Food and Drug Administration Web site. http://www fda.gov/oc/initiatives/ criticalpath/whitepaper .html. Published March 16, 2004. Accessed September 3, 2007.
18. Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2003; 2(9):695-702.
19. Gilbert J, Henske P, Singh A. Rebuilding big pharma's business model. In Vivo 2003;21: 73-80.
20. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Diseov 2004;3(8): 673-683.
21. Tufts Center for the Study of Drug Development. Backgrounder: how new drugs move through the development and approval process, Boston, Mass, November 2001; and Gilbert J, Henske P, Singh A. "Rebuilding big pharma's business model." In Vivo, the Business & Medicine Report, Windhover Information, Vol 21, No 10, November 2003.
22. Nunn AD. The cost of developing imaging agents for routine clinical use. Invest Radiol 2006;41(3):206-212.
23. BIO-TECH report no. 200, the market for PET radiopharmaceuticals & PET imaging, http://biotechsystems.com/reports/200 /default.asp. Accessed September 3, 2007.
24. Ad BIO-TECH report no. 190, the U.S. market for medical imaging contrast media. http://biotechsystems.com/reports/190 /default.asp. Accessed September 3, 2007.
25. Contrast agents for medical imaging. Business Communications Company. http: www.bccresearch.com/RepTemplate.cfm ?reportID=286&RepDet=HLT&cat= hlc &target=repdetail.cfm. Accessed September 3, 2007.
26. Mathieu MP, ed. PAREXEL's pharmaceutical R&D statistical sourcebook 2002/2003. Waltham, Mass: Parexel International, 2002.
27. Windhover's in vivo: the business and medicine report, Bain drug economics model. Norwalk, Conn: Windhover Information, 2003.
28. Radioactive Drug Research Committee (RDRC) program. U.S. Food and Drug Administration Web site. http://www.fda .gov/cder/regulatory/RDRC/default.htm #RDRC. Created September 20, 2005. Updated November 21, 2005. Accessed September 3, 2007.
29. Investigational new drug (IND) application process. U.S. Food and Drug Administration Web site. http://www.fda.gov/cder /regulatory/applications/ ind_page_1.htm. Updated May 3, 2007. Accessed September 3, 2007.
30. Drug development, and review definitions. U.S. Food and Drug Administration Web site. http://www.fda.gov/cder/about/smallbiz /definitions.htm. Updated June 4, 2001. Accessed September 3, 2007.
31. Guidance documents. U.S. Food and Drug Administration Web site. http://www.fda .gov/cder/guidance/index.htm. Created June 16, 2004. Updated August 28, 2007. Accessed September 3, 2007.
32. Guidance for industry: developing medical imaging drug and biological products. I. Conducting safety assessments. U.S. Food and Drug Administration Web site. http://www .fda.gov/cder/guidance/5742prt1.pdf. Published June 2004. Accessed September 3, 2007.
33. Guidance for industry: developing medical imaging drug and biological products. II. Clinical indications. U.S. Food and Drug Administration Web site. http://www.fda.gov /cder/guidance/5742prt2.pdf. Published June 2004. Accessed September 3, 2007.
34. Guidance for industry: developing medical imaging drug and biological products. III. Design, analysis, and interpretation of clinical studies. U.S. Food and Drug Administration Web site. http://www.fda.gov/cder/guidance /5742prt3.pdf. Published June 2004. Accessed September 3, 2007.
35. Code of Federal Regulations, title 21, volume 5, 21 CFR §361.1. U.S. Food and Drug Administration Web site. http://www.accessdata.fda .gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm ?FR=361.1. Revised April 1, 2005. Accessed September 3, 2007.
36. Code of Federal Regulations, title 21, volume 5, CFR §312.23. U.S. Food and Drug Administration Web site. http://a257.g.akamaitech.net〉 /7/257/2422/04nov20031500/edocket.access .gpo.gov/cfr_2003/aprqtr/21cfr312.23. htm. Revised April 1, 2003. Accessed September 3, 2007.
37. Investigational new drug application (IND), FDA form 1571. U.S. Food and Drug Administration Web site. http://www.fda.gov /opacom/morechoices/fdaforms/ FDA-1571 .pdf. Created April 2006. Accessed September 3, 2007.
38. Statement of investigator, FDA form 1572. U.S. Food and Drug Administration Web site. http://www.fda.gov/opacom/morechoices /fdaforms/FDA-1572.pdf. Created May 2006. Accessed September 3, 2007.
39. Investigational new drug (IND) annual report requirements. U.S. Food and Drug Administration Web site. http://a257.g.akamaitech.net/7/257 /2422/04nov20031500/edocket.access .gpo.gov/cfr_2003/aprqtr/pdf/21cfr312 .33.pdf. Revised March 4, 2002. Accessed September 3, 2007.
40. Guidance for industry, investigators, and reviewers, exploratory IND studies. U.S. Food and Drug Administration Web site. http: //www.fda.gov/cder/ guidance/7086fnl.htm. Created January 12, 2006. Accessed September 3, 2007.
41. Bodenheimer T. High and rising health care costs. I. Seeking an explanation. Ann Intern Med 2005;142(10):847-854.
42. Bodenheimer T. High and rising health care costs. II. Technologic innovation. Ann intern Med 2005;142(11):932-937.
43. Mission, vision and goals, Center for Medicare and Medicaid Services (CMS). U.S. Department of Health and Human Services Web site. http://www.cms.hhs.gov /MissionVisionGoals/. Modified February 12, 2007. Accessed September 3, 2007.
44. CMS financial report, fiscal year 2005, Center for Medicare and Medicaid Services (CMS). U.S. Department of Health and Human Services Web site. http://www.cms .hhs.gov/CFOReport/Downloads/2005_CMS _Financial_Report.pdf. Created November 2005. Accessed September 3, 2007.
45. Tunis SR. A clinical research strategy to support shared decision making. Health Aff (Millwood) 2005;24(1):180-184.
46. Tunis SR. Why Medicare has not established criteria for coverage decisions. N Engl J Med 2004;350(21):2196-2198.
47. Tunis SR, Kang JL. Improvements in Medicare coverage of new technology. Health Aff (Millwood) 2001;20(5):83-85.
48. Factors CMS considers in opening a national coverage determination, Center for Medicare and Medicaid Services (CMS). U.S. Department of Health and Human Services Web site. http://www.cms.hhs.gov/mcd /ncpc_view_document.asp?id= 6. Created April 11, 2006;Accessed September 3, 2007.
49. Factors CMS considers in commissioning external technology assessments, Center for Medicare and Medicaid Services (CMS). U.S. Department of Health and Human Services Web site. http://www.cms.hhs.gov /mcd/ncpc_view_document.asp?id= 7. Created April 11, 2006;Accessed September 3, 2007.
50. Factors CMS considers in referring topics to the Medicare Coverage Advisory Committee (MCAC) Center for Medicare and Medicaid Services (CMS). U.S. Department of Health and Human Services Web site. http://www.cms.hhs.gov/mcd/ ncpc _view_document.asp?id=10. Created December 12, 2006; Accessed September 3, 2007.
51. CMS has launched the Council on Technology and Innovation (CTI), Center for Medicare and Medicaid Services (CMS). U.S. Department of Health and Human Services Web site. http://www.cms.hhs.gov/council ontechinnov/. Modified December 14, 2005. Accessed September 3, 2007.
52. A time line of the various approvals, dates, and specific indications that are now covered and reimbursed for PET can be found at the Center for Medicare and Medicaid Services (CMS). U.S. Department of Health and Human Services Web site. http://www.cms.hhs .gov/mcd/viewncd.asp?ncd_id=220.6&ncd
53. National Oncologic PET Registry (NOPR) Web site for up to date information on CMS covered indications for FDG-PET in oncology. http: //www.cancerpetregistry.org/indications.htm. Created October 7, 2006. Accessed September 3, 2007.
54. Gambhir SS, Czernin J, Schwimmer J. Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S.
55. Decision memo for magnetic resonance spectroscopy for brain tumors (CAG-00141N), Center for Medicare and Medicaid Services (CMS). U.S. Department of Health and Human Services Web site. http://www.cms.hhs.gov/mcd/ viewdecisionmemo.asp?id=52. Created January 29, 2004. Updated July 7, 2007. Accessed September 3, 2007.
56. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290(12):1624-1632.
57. Factors CMS considers in making a determination of coverage with evidence development, Center for Medicare and Medicaid Services (CMS). U.S. Department of Health and Human Services Web site. http://www.cms.hhs.gov /mcd/ncpc_view_document.asp?id=8. Created July 12, 2006; Accessed September 3, 2007.
58. National Oncologic PET Registry Web site. http://www.cancerpetregistry. org/. Accessed September 3, 2007.
59. NCD for PET (FDG) for dementia and neurodegenerative diseases. Center for Medicare and Medicaid Services (CMS). U.S. Department of Health and Human Services Web site. http://www.cms.hhs.gov/mcd/viewncd. asp?ncd_id=220.6. 13&ncd_version=2& basket=ncd%3A220%2E6%2E13%3A2% 3APET+%28FDG%29+for+Dementia+ and+Neurodegenerative+Diseases. Created January 28, 2003. Updated August 14, 2007. Accessed September 30, 2007.